Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer Results of the Phase II Randomized ABIGAIL Study (BO21015)

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based... ORIGINAL ARTICLE A Correlative Biomarker Analysis of the Combination of  Bevacizumab and Carboplatin-Based Chemotherapy for  Advanced Nonsquamous Non–Small-Cell Lung Cancer Results of the Phase II Randomized ABIGAIL Study (BO21015) Tony Mok, MD,* Vera Gorbunova, MD,† Erzsebet Juhasz, MD,‡ Barna Szima, MD,§ Olga Burdaeva, MD,║ Sergey Orlov, MD, PhD,║ Chong-Jen Yu, MD, PhD,¶ Venice Archer, MD,# Magalie Hilton, MSc,** Paul Delmar, PhD,** Celine Pallaud, PhD,** and Martin Reck, MD, PhD†† Results: Patients were randomized to receive chemotherapy plus Introduction: Avastin Biomarkers In lunG And 3D Innovative 7.5 mg/kg (n = 154) or 15 mg/kg (n = 149) bevacizumab. For the anaLysis (ABIGAIL), which is a phase II, open-label, randomized primary analysis, none of the baseline plasma biomarkers corre- study, investigated correlations between biomarkers and best overall lated with best overall response. Exploratory analyses showed that response to bevacizumab plus platinum-doublet chemotherapy for low VEGF-A levels were associated with longer progression-free patients with advanced/recurrent non–small-cell lung cancer. survival (7.4 versus 6.1 months; hazard ratio, 1.57; 95% confidence Methods: Patients received bevacizumab (7.5 or 15 mg/kg, 3-weekly intervals, 1.17 to 2.09; p = 0.002) and overall survival (19.8 versus until disease progression/unacceptable toxicity) plus carboplatin/ 11.1 months; hazard ratio, 1.57; 95% confidence interval, 1.15–2.13; gemcitabine or carboplatin/paclitaxel (maximum six cycles). Plasma p = 0.004) compared with these http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer Results of the Phase II Randomized ABIGAIL Study (BO21015)

Reck, Martin
Journal of Thoracic Oncology , Volume 9 (6) – Jun 1, 2014
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/a-correlative-biomarker-analysis-of-the-combination-of-bevacizumab-and-R05ZtfwnNW

References (27)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000160
pmid
24807156
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE A Correlative Biomarker Analysis of the Combination of  Bevacizumab and Carboplatin-Based Chemotherapy for  Advanced Nonsquamous Non–Small-Cell Lung Cancer Results of the Phase II Randomized ABIGAIL Study (BO21015) Tony Mok, MD,* Vera Gorbunova, MD,† Erzsebet Juhasz, MD,‡ Barna Szima, MD,§ Olga Burdaeva, MD,║ Sergey Orlov, MD, PhD,║ Chong-Jen Yu, MD, PhD,¶ Venice Archer, MD,# Magalie Hilton, MSc,** Paul Delmar, PhD,** Celine Pallaud, PhD,** and Martin Reck, MD, PhD†† Results: Patients were randomized to receive chemotherapy plus Introduction: Avastin Biomarkers In lunG And 3D Innovative 7.5 mg/kg (n = 154) or 15 mg/kg (n = 149) bevacizumab. For the anaLysis (ABIGAIL), which is a phase II, open-label, randomized primary analysis, none of the baseline plasma biomarkers corre- study, investigated correlations between biomarkers and best overall lated with best overall response. Exploratory analyses showed that response to bevacizumab plus platinum-doublet chemotherapy for low VEGF-A levels were associated with longer progression-free patients with advanced/recurrent non–small-cell lung cancer. survival (7.4 versus 6.1 months; hazard ratio, 1.57; 95% confidence Methods: Patients received bevacizumab (7.5 or 15 mg/kg, 3-weekly intervals, 1.17 to 2.09; p = 0.002) and overall survival (19.8 versus until disease progression/unacceptable toxicity) plus carboplatin/ 11.1 months; hazard ratio, 1.57; 95% confidence interval, 1.15–2.13; gemcitabine or carboplatin/paclitaxel (maximum six cycles). Plasma p = 0.004) compared with these

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2014

There are no references for this article.